...
首页> 外文期刊>Molecular cancer therapeutics >Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis
【24h】

Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis

机译:白血病相关融合蛋白的表达提高了对组蛋白脱乙酰基酶抑制剂诱导的DNA损伤和凋亡的敏感性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Histone deacetylase inhibitors (HDI) show activity in a broad range of hematologic and solid malignancies, yet the percentage of patients in any given malignancy who experience a meaningful clinical response remains small. In this study, we sought to investigate HDI efficacy in acute myeloid leukemia (AML) cells expressing leukemia-associated fusion proteins (LAFP). HDIs have been shown to induce apoptosis, in part, through accumulation ofDNA damage and inhibition of DNArepair. LAFPs have been correlated with aDNArepair- deficient phenotype, which may make them more sensitive to HDI-induced DNA damage. We found that expression of the LAFPs PLZF-RARa, PML-RARa, and RUNX1-ETO (AML1-ETO) increased sensitivity to DNA damage and apoptosis induced by the HDI vorinostat. The increase in apoptosis correlated with an enhanced downregulation of the prosurvival protein BCL2. Vorinostat also induced expression of the cell-cycle regulators p19INK4D and p21WAF1 and triggered a G2-M cell cycle arrest to a greater extent in LAFP-expressing cells. The combination of LAFP and vorinostat further led to a greater downregulation of several base excision repair (BER) enzymes. These BER genes represent biomarker candidates for response to HDI-induced DNA damage. Notably, repair of vorinostat- inducedDNAdouble-strand breaks was found to be impaired in PLZFRARa- expressing cells, suggesting a mechanism by which LAFP expression and HDI treatment cooperate to cause an accumulation of damaged DNA. These data support the continued study of HDI-based treatment regimens in LAFP-positive AMLs. Mol Cancer Ther; 12(8); 1591-604.
机译:组蛋白脱乙酰基酶抑制剂(HDI)在广泛的血液系统和实体恶性肿瘤中均表现出活性,但是在任何给定的恶性肿瘤中发生有意义的临床反应的患者百分比仍然很小。在这项研究中,我们试图调查HDI在表达白血病相关融合蛋白(LAFP)的急性髓样白血病(AML)细胞中的功效。已经显示出HDI部分地通过DNA损伤的积累和DNA修复的抑制来诱导凋亡。 LAFPs与DNA修复缺陷型有关,这可能使它们对HDI诱导的DNA损伤更敏感。我们发现,LAFPs PLZF-RARa,PML-RARa和RUNX1-ETO(AML1-ETO)的表达增加了对HDI伏立诺他诱导的DNA损伤和细胞凋亡的敏感性。凋亡的增加与生存蛋白BCL2的下调增强有关。伏立诺他还诱导细胞周期调节因子p19INK4D和p21WAF1的表达,并在表达LAFP的细胞中更大程度地触发了G2-M细胞周期的阻滞。 LAFP和伏立诺他的组合进一步导致几种碱基切除修复(BER)酶的更大下调。这些BER基因代表了对HDI诱导的DNA损伤反应的生物标志物候选物。值得注意的是,在PLZFRARa表达细胞中发现伏立诺他诱导的DNA双链断裂的修复受到损害,这表明LAFP表达和HDI处理协同作用导致受损DNA积累的机制。这些数据支持对LAFP阳性AML中基于HDI的治疗方案的持续研究。分子癌疗法; 12(8); 1591-604。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号